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ABSTRACT
Introduction: Immediate breast reconstruction (IBR)
is routinely offered to improve quality of life for women
with breast cancer requiring a mastectomy, but there
are concerns that more complex surgery may delay the
delivery of adjuvant oncological treatments and
compromise long-term oncological outcomes. High-
quality evidence, however, is lacking. iBRA-2 is a
national prospective multicentre cohort study that aims
to investigate the effect of IBR on the delivery of
adjuvant therapy.
Methods and analysis: Breast and plastic surgery
centres in the UK performing mastectomy with or
without (±) IBR will be invited to participate in the
study through the trainee research collaborative
network. All women undergoing mastectomy ± IBR for
breast cancer between 1 July and 31 December 2016
will be included. Patient demographics, operative,
oncological and complication data will be collected.
Time from last definitive cancer surgery to first
adjuvant treatment for patients undergoing
mastectomy ± IBR will be compared to determine the
impact that IBR has on the time of delivery of adjuvant
therapy. Prospective data on 3000 patients from ∼50
centres are anticipated.
Ethics and dissemination: Research ethics approval
is not required for this study. This has been confirmed
using the online Health Research Authority decision
tool. This novel study will explore whether IBR impacts
the time to delivery of adjuvant therapy. The study will
provide valuable information to help patients and
surgeons make more informed decisions about their
surgical options. Dissemination of the study protocol
will be via the Mammary Fold Academic and Research
Collaborative (MFAC) and the Reconstructive Surgery
Trials Network (RSTN), the Association of Breast
Surgery (ABS) and the British Association of Plastic,
Reconstructive and Aesthetic Surgeons (BAPRAS).
Participating units will have access to their own data
and collective results will be presented at relevant
surgical conferences and published in appropriate
peer-reviewed journals.
INTRODUCTION
Approximately 51 000 women will be diag-
nosed with breast cancer each year,1 of
whom, up to 40% may require a mastectomy
as the primary surgical treatment.2 The loss
Strengths and limitations of this study
▪ Large multicentre prospective study involving
data collection from breast and plastic surgical
units across the UK.
▪ Will produce valuable data regarding the impact
of immediate breast reconstruction on the time
to delivery of adjuvant therapy which will help
inform decision-making for patients and
surgeons.
▪ Will strengthen the collaborative network
between breast and plastic surgical trainees and
consultants to facilitate the delivery of future
research.
▪ Observational design will not address causality.
▪ Short-term data collection will not allow the
long-term impact of delays to adjuvant therapy
to be assessed.
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of breast can profoundly impact a woman’s quality of life
and body image.3 Immediate breast reconstruction
(IBR) is routinely offered in the UK to improve
outcomes.4
While IBR may improve psychosocial outcomes for
women facing mastectomy, these beneﬁts need to be
weighed against the increased risk of complications asso-
ciated with more complex procedures. The National
Mastectomy and Breast Reconstruction Audit (NMBRA)
reported a stepwise increase in complication rates with
procedure complexity with 10% of patients undergoing
mastectomy experiencing a postoperative complication
compared with 11% of patients undergoing an implant-
based procedures; 16% of patients undergoing a
pedicled ﬂap and 18% of those undergoing immediate
free-ﬂap reconstruction.5 These complication rates are
likely to represent an underestimation of the burden of
postoperative morbidity as signiﬁcant number of compli-
cations, in particular wound infections and seromas,
continue to occur after discharge.
Complication rates following IBR are important as they
may lead to the delay or omission of adjuvant cancer ther-
apies in the form of adjuvant chemotherapy or biological
therapy and postmastectomy radiotherapy. The clinical
signiﬁcance of short delays is unclear, but delays of
between 76 and 12 weeks7 have been shown to adversely
impact on key oncological outcomes, including
recurrence-free and overall survival. Furthermore, a
recent meta-analysis suggests a 15% decrease in overall
survival for every 4-week delay in the delivery of adjuvant
chemotherapy.8 Similarly, delays to radiotherapy adversely
impact oncological outcomes, although the timeframes
are less well established. An early meta-analysis suggested
an increased risk of locoregional recurrence if radiother-
apy was delayed by more than 8 weeks following surgery.9
More recent studies, however, suggest there to be no
adverse effect on disease-free or overall survival if radio-
therapy is started within 3 months of surgery,10–13 with
one large UK cohort study showing no deleterious effects
with delays of up to 20 weeks.10 To ensure timely delivery
of adjuvant therapies, the National Institute of Health
and Care Excellence (NICE) recommends that adjuvant
chemotherapy or radiotherapy should be started ‘as soon
as clinically possible [and] within 31 days of completion
of surgery in patients with early breast cancer having
these treatments’.4
Evidence regarding the impact of IBR on the deli-
very of adjuvant therapy, however, is inconsistent.
Observational studies have generated conﬂicting
results,14–39 and a recent systematic review40 of 14 studies
failed to demonstrate any convincing adverse impact of
IBR on the time to adjuvant treatments. This review,
however, was based on small, poorly designed single-
centre often retrospective case-series, the results of
which cannot be relied on. Therefore, there is a lack of
high-quality evidence to demonstrate the impact of IBR
on the delivery of adjuvant therapies compared with
mastectomy alone. Randomised controlled trials (RCTs)
provide the best evidence of treatment effect, but in this
context are largely inappropriate. A large-scale prospect-
ive cohort study is therefore required to provide high-
quality evidence regarding the impact of IBR on the
delivery of adjuvant therapy to allow patients and sur-
geons to make more informed decisions about potential
treatment options.
The challenges to the design and conduct of
large-scale cohort studies are well documented, but the
trainee collaborative model has emerged as a time-
effective and cost-effective means of delivering high-
quality prospective research and audit.41–44 The ongoing
iBRA (implant Breast Reconstruction evAluation) study
(ISRCTN37664281),45 a national prospective cohort
study to explore the feasibility, design and conduct of a
pragmatic RCT in implant-based breast surgery, has
demonstrated the trainee collaborative model is transfer-
able to breast and plastic surgery, and has established a
network of centres willing and able to participate in
future projects. It is anticipated that this network of
highly motivated and enthusiastic breast and plastic sur-
gical trainees and consultants can be used to deliver a
new study exploring the impact of IBR on the timing of
adjuvant therapy.
METHODS AND ANALYSIS
Primary aim
The aim of iBRA-2 is to work with the Breast
Reconstruction Research Collaborative network to evalu-
ate the impact of IBR on the time to delivery of adjuvant
therapy. The group undergoing mastectomy without IBR
and the group undergoing mastectomy with IBR will be
compared with respect to:
1. the rate of postoperative complications,
2. the requirement for adjuvant chemotherapy and/or
radiotherapy,
3. the experience of a delay to or omission of their adju-
vant therapy as a result of a surgical complication,
4. the time to adjuvant therapy.
Other non-comparative objectives are to:
5. identify risk factors of patients who experience a
delay to or omission of their adjuvant therapy as a
result of surgical complication,
6. explore the impact of delay to adjuvant therapy on
key oncological outcomes, including locoregional
recurrence; metastatic disease and breast cancer-
speciﬁc death at 5 and 10 years,
7. generate high-quality data to inform decision-making
for patients and health professionals,
8. build and strengthen the collaborative network
created by the iBRA study to include oncologists and
build future research capacity.
Hypothesis
IBR following mastectomy for breast cancer does not
increase the time to delivery of adjuvant therapy com-
pared with mastectomy alone.
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Study design
We plan to undertake a national prospective multicentre
cohort study using the research collaborative model pre-
viously reported42 43 coordinated by the iBRA-2 Steering
Group.
Setting
Any breast or plastic surgical unit in the UK performing
mastectomy with or without IBR will be eligible to par-
ticipate to the study. Units will be invited to participate
in the study through the Association of Breast Surgery
(ABS), the Mammary Fold breast trainees’ group (MF),
the Association of Surgeons in Training (ASiT), the
Reconstructive Surgery Trials Network (RSTN), the
British Association of Plastic Reconstructive and
Aesthetic Surgeons (BAPRAS) and the national research
collaborative network (NRCN).
Participants
Inclusion criteria: All women over the age of 18 who are
undergoing a mastectomy with or without immediate
reconstruction for pre-invasive or invasive breast cancer
with curative intent.
Exclusion criteria: Women undergoing mastectomy for
risk-reduction only; however, women who are undergo-
ing a contralateral risk-reducing mastectomy at the same
time as a therapeutic mastectomy for invasive or preinva-
sive disease may be included. Patients undergoing
partial mastectomy, including lumpectomy or wide-local
excision with volume replacement techniques (latissimus
dorsi mini ﬂaps; lateral intercostal perforator or thoraco-
dorsal artery perforator ﬂaps) or therapeutic mammo-
plasty, and patients with distant metastatic disease will be
excluded.
Outcome measures
The primary outcome measure will be time in days from
last deﬁnitive cancer surgery to the ﬁrst adjuvant treat-
ment. The last deﬁnitive cancer surgery will most com-
monly be the index mastectomy procedure, but may
include completion axillary clearance or re-excision of
margins as determined on review of the surgical path-
ology by the multidisciplinary team (MDT). Unplanned
surgery such as implant explantation, debridement of
skin necrosis, washout of haematoma or return to theatre
for ﬂap failure constitute complications and will not be
classiﬁed as last deﬁnitive surgery for the purposes of this
study. First adjuvant therapy will be deﬁned as the ﬁrst
dose of chemotherapy or the ﬁrst fraction of radiother-
apy. Time to endocrine therapy will not be included. This
deﬁnition is based on the National Institute for Health
and Care Excellence guidance for early and locally
advanced breast cancer (CG80) which states that adju-
vant chemotherapy or radiotherapy should be started ‘as
soon as clinically possible [and] within 31 days of comple-
tion of surgery in patients with early breast cancer having
these treatments’.4 In patients for whom more than one
modality of adjuvant treatment is recommended, only
the start date for the ﬁrst adjuvant therapy will be
recorded. Secondary outcomes are listed in table 1.
Data collection
It is expected that participating centres will recruit con-
secutive patients into the audit.
Patients undergoing mastectomy with or without
immediate reconstruction will be identiﬁed prospectively
from clinics, MDT meetings and theatre lists.
Simple demographic, comorbidity, operative and
oncology data will be collected on all patients. Decisions
regarding the recommendation for adjuvant treatment
will be identiﬁed from the postoperative MDT meeting.
For patients in whom adjuvant therapy is recom-
mended at the postoperative MDT meeting, data will be
collected on whether or not the offer was accepted. In
those patients electing to receive adjuvant therapy, date
of the ﬁrst treatment will be collected.
Data regarding complications, re-admission and re-
operation will be collected prospectively until the
patient begins adjuvant therapy or a decision is made
that they will not undergo adjuvant therapy due to the
complications they have experienced. Preliminary work
suggests that, despite NICE guidelines, adjuvant therapy
is unlikely to start earlier than 6 weeks postoperatively.
For patients not requiring or electing not to receive
adjuvant therapy, therefore, data collection will continue
for 6 weeks following their last deﬁnitive cancer surgery
either by clinical or note review in those not attending
for follow-up. The required data ﬁelds are shown in
table 2 and deﬁnitions and categorisation of complica-
tions summarised in table 3.
Oncological outcomes (locoregional recurrence,
distant metastasis and breast cancer-speciﬁc death) will
be evaluated at 5 and 10 years following initial surgery by
searching the UK Cancer Registry database. This phase
of the study will be undertaken centrally by the iBRA-2
study team subject to appropriate ethical approval.
Data will be recorded in an anonymised format using
a unique alphanumeric study identiﬁcation number on
a secure web-based database (REDCap) designed by
Vanderbilt University47–49 (http://www.projectredcap.
org/). Advanced data logic will be used such that only
data ﬁelds relevant to the procedure and indication
selected will be displayed in later data collection forms.
It is anticipated this will reduce the burden of participa-
tion for collaborators and optimise the quality of data
collected during the study.
The data forms will be extensively trialled in a three-
centre pilot prior to national rollout of the study. This
will validate the logic used; ensure the forms are com-
plete and user-friendly and allow for any errors to be
corrected prior to main study initiation.
Participating centres will be required to maintain and
securely store an Excel spreadsheet linking study ID
numbers with patient NHS numbers to allow long-term
oncological outcomes to be evaluated at 5 and 10 years
postoperatively.
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Data validation and management
For quality assurance purposes, the consultant principal
investigator at selected sites will be asked to identify an
independent person to validate a proportion of the sub-
mitted data. These cases will be selected at random.
Overall, ∼5% of the data sets will be independently vali-
dated. The independent assessors will also be asked to
examine theatre logbooks, operating diaries and Trust
computer systems to check case ascertainment. If con-
cordance between the number of cases submitted on
REDcap and those identiﬁed independently is <90%,
the Unit’s data will be excluded from the analysis. This
is consistent with the quality assurance procedure used
in other large collaborative audit projects.50
Data collection will occur in accordance with Caldicott
II principles (http://systems.hscic.gov.uk/infogov/
caldicott/caldresources). Data for each patient will be
anonymised using a unique alphanumeric study identiﬁ-
cation number. Collaborators will be ask to store an
Excel spreadsheet linking study ID to NHS number on a
secure server locally to ensure patients are appropriately
followed-up during the study. No patient identiﬁable
data will be recorded centrally for the purpose of the
audit.
Following the completion of data collection, appropri-
ate ethical approvals will be obtained to allow the
spreadsheets linking study ID to NHS number to be col-
lated centrally. Only centres with ethical approval will be
permitted to contribute to this phase of the study. The
data will be stored securely in a central location until
5 years following study completion. Oncological out-
comes will then be determined using a UK Cancer
Table 1 Secondary outcome measures
Outcome measure Definition
Postoperative complications Any postoperative complication occurring before the first adjuvant treatment or within
30 days of surgery for patients not requiring adjuvant chemotherapy or radiotherapy
To be classified by the Clavien-Dindo classification of complications as applied to
breast surgery46 with specific reference to:
Mastectomy and breast reconstruction specific complications: seroma; haematoma;
infection; mastectomy skin flap necrosis; nipple necrosis; wound dehiscence; implant
loss; donor site skin necrosis; flap salvage; partial and full flap necrosis/failure
Systemic complications: Deep vein thrombosis, pulmonary embolism, myocardial
infarction; lower respiratory tract infection; blood transfusion; unplanned admission to
high dependency or intensive therapy units; urinary tract infection
Readmission to hospital Any readmission to hospital following discharge home after mastectomy ± immediate
breast reconstruction surgery directly related to the procedure with either local or
systemic complications in the time prior to the delivery of the first adjuvant treatment or
within 30 days of surgery in those not requiring chemo or radiotherapy
Unplanned reoperation/return to
theatre
Any unplanned re-operation or return to the operating theatre prior to the delivery of the
first adjuvant therapy or in the 30 days following surgery to deal with any complication
of the mastectomy or reconstruction
Any planned return to theatre for additional oncological surgery, such as completion
axillary clearance, as decided by the multidisciplinary team on review of surgical
pathology will NOT be included in this category
Use of adjuvant therapy Number (proportion) of patients undergoing mastectomy ± immediate breast
reconstruction who require adjuvant
Chemotherapy
Biological therapy
Radiotherapy
Omission, modification or delay of
adjuvant therapy
Number (proportion) of patients undergoing mastectomy ± immediate breast
reconstruction whose planned adjuvant chemotherapy/biological therapy or
radiotherapy is
Omitted (not given, despite MDT recommendation)
Modified (dose/regimen changed from planned/standard treatment)
Delayed (not given at time scheduled following oncology appointment) as a result of a
postoperative complication
Long-term oncological outcomes Number (proportion) of patients with and without a delay or omission of planned
adjuvant chemotherapy or radiotherapy who at 5 and 10 years following their initial
surgery experience
Locoregional recurrence, defined as a histologically confirmed breast cancer
recurrence within the ipsilateral breast or axilla
Distant metastasis, defined as radiologically or histologically confirmed distant
metastatic breast cancer
Breast cancer specific-death, defined as death directly attributed to the disease
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Table 2 Data fields for the iBRA-2 study
Field Options (definitions)
Section 1: demographic data
Age Age at diagnosis in years
Height In metres
Weight In kilograms
Body mass index Actual BMI will be collected and categorised as—underweight (<18.5 kg/m2)/normal
weight (18.5–24.9 kg/m2)/overweight (25–29.9 kg/m2)/obese (30–34.9 kg/m2)/
severely obese (35–39.9 kg/m2)
Morbid obesity (>40 kg/m2)
Smoking status Current smoker/ex-smoker >6 weeks/non-smoker
Diabetic Yes/no
Other comorbidities Ischaemic heart disease (yes/no); current steroid therapy (yes/no); other
immunosuppressive therapy (yes/no); connective tissue disease (yes/no); other
comorbidity (yes/no) with details
Prior and neoadjuvant treatments
Previous radiotherapy to ipsilateral
breast
Yes/no
Neoadjuvant chemotherapy within
4–6 weeks of surgery
Yes/no
Neoadjuvant endocrine therapy Yes/no
Neoadjuvant radiotherapy Yes/no
Previous surgery to ipsilateral breast Wide-local excision (yes/no, if yes, date MM/YY);
Therapeutic mammaplasty (yes/no, if yes, date MM/YY);
Breast reduction (yes/no, if yes, date MM/YY);
Breast augmentation (yes/no, if yes, date MM/YY);
Other (yes/no, if yes, date MM/YY): State procedure
Previous surgery to ipsilateral axilla Sentinel node biopsy with wide-local excision (yes/no, if yes, date MM/YY);
Stand-alone sentinel node biopsy (yes/no, if yes, date MM/YY);
Axillary sample (yes/no, if yes, date MM/YY);
Axillary clearance (yes/no, if yes, date MM/YY)
Section 2: operative data
Date of mastectomy±reconstruction Day/month/year
ASA grade 1. Normal healthy individual
2. Mild systemic disease that does not limit activities
3. Severe systemic disease that limits activities but is not incapacitating
4. Incapacitating systemic disease which is constantly life-threatening
Antibiotic use Prophylactic (<24 hours)/1–5 days/extended course (5+ days)/until drains removed/
other
Type of skin prep used at the time of
surgery
Iodine/Chlorhexidine/2% chlorprep/other
Procedure details collected for RIGHT and LEFT breasts separately
Procedure performed None
Mastectomy only
Skin-sparing (nipple sacrificing) mastectomy and immediate breast reconstruction
Nipple-sparing mastectomy and immediate breast reconstruction
Skin reducing (Wise pattern) mastectomy and immediate breast reconstruction
Wide-local excision
Reduction/mastopexy
Augmentation
If IBR, type of reconstruction
performed
Implant-based/pedicled flap/free flap/other
If patient undergoing implant reconstruction
Implant reconstruction—planned
procedure
One-stage reconstruction—insertion of permanent implant at initial surgery
Two-stage reconstruction—insertion of a tissue expander to be followed by insertion
of a definitive implant
Immediate-delayed reconstruction—insertion of a temporary expander in patients for
whom radiotherapy is anticipated with a plan to perform a definitive autologous
(tissue-based) reconstruction after radiotherapy is complete
Continued
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Table 2 Continued
Section 2: operative data
Date of mastectomy±reconstruction Day/month/year
Mode of lower pole coverage None/fascial or complete submuscular coverage/dermal sling/biological mesh (eg,
Strattice)/synthetic mesh (eg, TiLOOP)/prepectoral implant with total ADM coverage,
for example, BRAXON/prepectoral implant with dermal sling/ADM
Details of product for lower pole
coverage
Stattice/SurgiMend/Native/BioDesign/Veritas/SERI/TiLOOP/TIGR/other
Prosthesis details Fixed volume implant (size in ccs)
Temporary expander (volume of saline inserted in ml)
Combined implant, for example, Beckers (silicone component (g), size when fully
expanded, volume of saline inserted in ml)
Polyurethene implant (yes/no)
If patient undergoing flap-based reconstruction
Type of pedicled flap performed Autologous LD flap (no implant)/LD with implant/Pedicled TRAM/other
If LD with implant, prosthesis details Fixed volume implant (size in ccs)
Temporary expander (volume of saline inserted in ml)
Combined implant, for example, Beckers (silicone component (g), size when fully
expanded, volume of saline inserted in ml)
Polyurethene implant (yes/no)
Type of free flap performed Free TRAM/DIEP/SIEA/SGAP/IGAP/TUG/other
Indication for surgery Malignancy (invasive/DCIS)—first operation/malignancy (invasive/DCIS)—following
failed BCS (WLE/TM)/risk reduction/symmetrisation
If failed BCS (positive margins) date
of initial surgery
Day/month/year
Grade of primary operating surgeon Consultant/SAS doctor/Senior trainee (ST8+ or OPF)/ST6-7/ST5 or below
Mastectomy weight Grams
Axillary surgery None/sentinel node biopsy/axillary sample/axillary clearance/previous axillary staging
Section 3: postoperative oncology and MDT outcomes
Pathology details for RIGHT and LEFT breasts will be collected separately
For patients having neoadjuvant chemotherapy,
complete pathological response? Yes/no
Invasive status Invasive/DCIS
Grade of invasive disease/DCIS 1. Low grade (DCIS) or well differentiated (invasive)
2. Intermediate grade (DCIS) or moderately differentiated (invasive)
3. High grade (DCIS) or poorly differentiated (invasive)
Histological type Ductal/lobular/mixed/other
Number of tumours Single tumour or multifocal/centric tumours
Size of invasive tumour mm (largest if >1 ipsilateral tumour)
Total size of lesion including DCIS In pathological specimen (mm)
On pretreatment diagnostic imaging (if neoadjuvant therapy) (mm)
Receptor status ER—positive/negative/not known
HER-2—positive/negative/not known
Ki67—high/low/not known
Lymphovascular invasion Yes/no/not known
Lymph node involvement Number of involved lymph nodes (macro-metastases only)
Total number of lymph nodes in pathological specimen
Plan from the therapeutic (postoperative) MDT
Date of postoperative MDT Day/month/year
Further oncological surgery required No/completion axillary clearance/re-excision of margins/other
Surgery, planned before adjuvant therapy Yes with date (day/month/year)
Treatments recommended
Chemotherapy Recommended by MDT/not recommended by MDT/for discussion with
patient/for Oncotype DX testing/chemotherapy already received
Biological therapy (eg, Herceptin) Recommended by MDT/not recommended by MDT
Radiotherapy to chest wall Recommended by MDT/not recommended by MDT/for discussion with
patient/already received
Continued
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Table 2 Continued
Section 3: postoperative oncology and MDT outcomes
Pathology details for RIGHT and LEFT breasts will be collected separately
For patients having neoadjuvant chemotherapy,
complete pathological response? Yes/no
If radiotherapy recommended With boost (yes/no)/to supraclavicular fossa (yes/no)/to axilla (yes/no)
Endocrine therapy Recommended by MDT/not recommended by MDT
Section 4: complication data
Please record any complications that occur BEFORE the start of adjuvant therapy OR in the first 6 weeks following
surgery in patients not requiring chemotherapy or radiotherapy
Postoperative complication experienced Yes/no
If yes—details of surgical complications
experienced (see table 3 for definitions)
Seroma/haematoma/infection/mastectomy skin flap necrosis/nipple
necrosis/wound dehiscence/implant loss/donor site skin necrosis/impaired
flap perfusion requiring return to theatre for exploration or revision of
anastomosis (flap salvage)/flap necrosis/other complication
Inhospital complications, including systemic
complications
Yes/no
If yes, complication(s) experienced (see table 3
for definitions)
Deep vein thrombosis/pulmonary embolism/myocardial infarction/lower
respiratory tract infection/blood transfusion/ unplanned admission to
intensive care/high-dependency unit/urinary tract infection/surgical
complication/other complication
Readmission to hospital Yes/no
If yes—date of readmission (day/month/year); reason for readmission
Return to theatre/reoperation Yes/no
If yes—date of reoperation (day/month/year); reason for reoperation
Section 5: adjuvant therapy data
This section documents the time from LAST CANCER surgery to FIRST ADJUVANT treatment, that is, first dose of
chemotherapy or first fraction of radiotherapy
Date of last definitive cancer surgery Day/month/year
Chemotherapy
Chemotherapy—if offered Patient accepts/patient declines
Oncotype DX risk stratification High risk/intermediate risk/low risk
Chemotherapy recommended based on Oncotype DX score Yes/no
Actual chemotherapy start date Day/month/year
Was planned treatment modified, delayed or omitted (not given)
due to a postoperative complication?
Not affected/delayed/modified/omitted completely/details
Radiotherapy
Radiotherapy—if offered Patient accepts/patient declines
Actual radiotherapy start date Day/month/year
Was planned treatment modified, delayed or omitted (not given)
due to a postoperative complication?
Not affected/delayed/modified/omitted completely/details
All adjuvant therapies
Did any factors impact on time to delivery of adjuvant therapy? Yes/no/unsure
If yes, please tick any factors that apply 1. Postoperative complication (yes/no)
2. Capacity issue—lack of medical oncology
appointments (yes/no)
3. Capacity issue—lack of clinical oncology (RT)
appointments (yes/no)
4. Capacity issue—lack of radiotherapy planning slots
(yes/no)
5. Capacity issue—lack of chemotherapy delivery slots
(yes/no)
6. Capacity issue—lack of radiotherapy delivery slots
(yes/no)
7. Waiting for staging CT scan or results (yes/no)
8. Waiting for staging bone scan or results (yes/no)
9. Waiting for staging PET scan or results (yes/no)
Continued
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Registry search. This search will be repeated to deter-
mine 10-year oncological outcomes.
Study data will be collected and managed using
REDCap electronic data capture tools hosted at the
University of Oxford.47 REDCap (Research Electronic
Data Capture) is a secure, web-based application
designed to support data capture for research studies,
providing (1) an intuitive interface for validated data
entry; (2) audit trails for tracking data manipulation and
export procedures; (3) automated export procedures for
seamless data downloads to common statistical packages
and (4) procedures for importing data from external
sources.
Anticipated recruitment
The recent MASDA (MAStectomy Decisions Audit) Study
(http://wmresearch.org.uk/) collected data on 1700
mastectomies ± IBR from 68 centres over a 3-month
period. It is therefore anticipated that given its increased
complexity, the iBRA-2 study will recruit ∼3000 patients
over a 6-month period. Assuming an IBR rate of
21%,51 52 this should include ∼630 reconstructions com-
prising ∼220 implant-only reconstructions; 170 autolo-
gous pedicled ﬂaps; 130 pedicled ﬂaps with implants and
90 free ﬂaps based on ﬁgures from the NMBRA.51
Study timelines
Data collection and analysis will be undertaken using
the following time line:
▸ May–June 2016—Three-centre pilot study, reﬁning of
data collection forms.
▸ March–June 2016—Registration of interest from
breast and plastic surgical units. Local audit approvals
obtained. Participating centres will be required to
have registered the study and obtained local
approvals prior to the main study start date of 1 July
2016.
▸ 1 July—31 December 2016—Main study patient
recruitment—patients undergoing mastectomy ± IBR
with operation dates between 1 July and 31
December 2016 are eligible for inclusion in the study.
▸ 28 February 2017—deadline for data submission via
REDCap.
▸ 1 May 2017—Data validation complete.
▸ 30 June 2017—Initial data analysis completed.
▸ July 2017—Ethical approval to store patient NHS
numbers to evaluate oncological outcomes.
▸ Early 2021—Assessment of 5-year oncological
outcomes.
▸ Early 2027—Assessment of 10-year oncological
outcomes.
Statistical analysis
The study report will be prepared according to the
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) reporting guidelines for obser-
vational studies.53 All data analysis will occur centrally by
the iBRA-2 study team with support from statisticians
and methodologists in the RCS Surgical Trials Centre
and the University of Liverpool Clinical Trials Research
Centre.
All outcomes will be summarised using descriptive sta-
tistics overall and split by group (mastectomy ± IBR).
Dichotomous, categorical and short ordinal outcomes
will be summarised using counts and percentages. Time
to adjuvant therapy will be summarised using the
Kaplan-Meier curves. Continuous and long ordinal out-
comes will be summarised by the mean, SD, minimum
and maximum (medians and IQRs will be reported for
skewed data).
Table 2 Continued
Section 5: adjuvant therapy data
This section documents the time from LAST CANCER surgery to FIRST ADJUVANT treatment, that is, first dose of
chemotherapy or first fraction of radiotherapy
Date of last definitive cancer surgery Day/month/year
10. Waiting for ECHO or results (yes/no)
11. Awaiting Oncotype DX results (yes/no)
12. Administrative delay—problems with booking
appointments (yes/no)
13. Patient choice (yes/no)
14. Patient-related issue, for example, needing
physiopreradiotherapy (yes/no)
15. Other (yes/no)—If yes, please give details
ADM, acellular dermal matrix; ASA, American society of Anesthesiology; BCS, breast-conserving surgery; CT, computerised tomography
scan; DCIS, ductal carcinoma in situ; DIEP, deep inferior epigastric perforator flap; ECHO, echocardiogram; ER, oestrogen receptor; HDU,
high-dependency unit; IBR, immediate breast reconstruction; IGAP, inferior gluteal artery perforator flap; ITU, intensive therapy unit; LD,
latissimus dorsi; MDT, multidisciplinary team; OPF, oncoplastic fellow; PET, positron emission tomography scan; RT, radiotherapy; SAS, Staff,
Associate Specialist and Specialty Doctors; SGAP, superior gluteal artery perforator flap; SIEA, superficial inferior epigastric artery perforator
flap; TM, therapeutic mammaplasty; TRAM, transverse rectus abdominus myocutaneous flap; TUG, transverse upper gracilis flap; WLE,
wide-local excision.
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Table 3 Definitions of complications
Any complication occurring as a direct result of the mastectomy ± breast reconstruction procedure
Complication Definition Classification/details
Surgical complications
Seroma A symptomatic collection of fluid in the mastectomy
or donor site or around the reconstructed breast
following surgery requiring aspiration
Minor—requiring 1–2
aspirations
Major—requiring 3 or more
aspirations
Haematoma A collection of blood in the mastectomy site/
reconstructed breast/donor site
Minor—managed
conservatively
Major 1—requiring aspiration
in clinic (no GA)
Major 2—requiring surgical
evacuation (under GA)
Infection A hot, red swollen wound/reconstructed breast/
donor site associated with one of the following; a
temperature, pus at the wound site, a raised white
cell count; a positive wound culture
Minor—requiring oral
antibiotics
Major 1—requiring admission
for intravenous antibiotics
Major 2—requiring surgical
drainage or debridement
(under GA)
Mastectomy skin flap necrosis Any area of skin loss on the mastectomy flaps Minor—managed
conservatively with dressings
Major 1—requiring
debridement in clinic (no GA)
Major 2—requiring surgical
debridement (under GA)
Nipple necrosis Any area of necrosis of the nipple areolar complex Minor—managed
conservatively with dressings
Major 1—requiring surgical
debridement
Major 2—complete nipple loss
Wound dehiscence Separation of the skin edges at the wound site
(breast or donor site)
Minor—managed
conservatively
Major—requiring return to
theatre for resuturing
Implant loss The unplanned and unexpected extirpation or loss
of the implant, including removal as a result of
infection, seroma, haematoma or skin necrosis
Yes/no
Donor site skin necrosis Any area of skin loss at the donor site (abdomen,
back, buttock or thigh)
Minor—managed
conservatively with dressings
Major 1—requiring
debridement in clinic (no GA)
Major 2—requiring surgical
debridement (under GA)
Impaired flap perfusion requiring
return to theatre for exploration/
revision of anastomosis
Concerns regarding perfusion of the flap requiring
a return to theatre for exploration ± revision of the
anastomosis
Yes/no
Flap necrosis Any necrosis of the free/pedicled tissue flap used
to reconstruct the breast
Partial flap necrosis requiring
surgical debridement
Total flap necrosis requiring
removal of flap
Other complication With details Yes/no
Inhospital complications
Any complication occurring during the period patient is in hospital for their index mastectomy ± reconstruction operation
Deep vein thrombosis A radiologically confirmed clot in the vessels of the lower
limb treated with anticoagulation
Yes/no
Pulmonary embolism A radiologically (CTPA or V/Q scan) confirmed clot in the
lung treated with anticoagulation
Yes/no
Continued
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Formal statistical testing for each outcome between
groups (mastectomy ± IBR) will be approached as
follows: Rates of postoperative complications, including
readmission and reoperation; requirement for adjuvant
therapy and delay or omission of planned adjuvant
chemotherapy or radiotherapy will be analysed using a
χ2 test and the effect estimate will be reported in terms
of the relative risk and 95% CI. Time to the delivery of
adjuvant therapy will be analysed using a log-rank test.
Delays to the delivery of adjuvant therapy will be ana-
lysed, controlling for risk factors of interest, using logis-
tic regression model. A p value of 0.05 or less will be
used to declare statistical signiﬁcance for all analyses.
Rather than adjust for multiplicity, relevant results from
other studies already reported in the literature will be
taken into account in the interpretation of results.
Results for each participating Trust will be summarised
and fed back to individual units to allow comparison
with national averages and ranges.
The statistical analysis of the 5-year and 10-year onco-
logical outcomes will be planned following completion
of the initial phase of the study.
DISCUSSION
IBR may improve psychosocial outcomes for women
requiring a mastectomy for breast cancer, but more
complex surgery may also result in complications that
could delay the delivery of important adjuvant
treatments and subsequently impact long-term onco-
logical outcomes. As oncological safety is the central
tenet of all oncoplastic surgery, the practice of IBR if
adjuvant therapy is anticipated is an area of considerable
controversy54 and one for which high-quality evidence is
currently lacking. The iBRA-2 study will generate much
needed novel data regarding the impact of IBR on the
time to delivery of adjuvant therapy compared with mast-
ectomy alone. It will provide valuable information that
may help patients and professionals make more
informed decisions about the type and timing of their
reconstructive surgery in the future. It will provide a
large, robust prospective observational data set that will
allow predictors for complications to be explored and
generate hypotheses that will lead to further work in this
area. The study will also generate valuable contemporan-
eous data relating to the practice of postmastectomy
radiotherapy following the emergence of data to suggest
signiﬁcant survival beneﬁt in a group of women with
one to three positive lymph nodes who would not trad-
itionally have been offered treatment.55 The proposed
assessment of locoregional recurrence, distant metasta-
ses and breast cancer-speciﬁc survival at 5 and 10 years
following surgery will provide much needed high-quality
data to determine the impact of delays to adjuvant
therapy on key oncological outcomes which will support
decision-making and practice. Finally, the study will
provide a further data cycle following the NMBRA5 to
Table 3 Continued
Inhospital complications
Myocardial infarction As confirmed by a rise in cardiac markers ± ECG
changes
Yes/no
Lower respiratory tract infection A lower respiratory tract infection diagnosed clinically by
the presence of clinical signs or radiologically and
treated with oral or intravenous antibiotics (Yes/no)
Yes/no
Blood transfusion Bleeding requiring blood transfusion following
mastectomy ± reconstructive surgery
Yes/no
Unplanned admission to
intensive care/
high-dependency unit
Any unplanned admission to HDU/ITU following
mastectomy ± reconstructive surgery
Yes/no
Urinary tract infection A microbiologically confirmed urinary tract infection Yes/no
Surgical complication As above Yes/no
Other complication Details Yes/no
Readmission and reoperation
Readmission Any readmission to hospital following discharge home
prior to the delivery of the first adjuvant therapy or in the
30 days following surgery in those not requiring chemo
or radiotherapy directly related to the procedure with
either local or systemic complications
Yes/no
If yes—date of readmission
(day/month/year) Reason for
readmission
Reoperation Any return to the operating theatre prior to the delivery of
the first adjuvant therapy or in the 30 days following
surgery to deal with any complication of the mastectomy
or reconstruction
Yes/no
If yes—date of reoperation
(day/month/year); Reason
for reoperation
CTPA, computerised tomography pulmonary angiography; ECG, electrocardiogram; GA, general anaesthetic; HDU, high-dependency unit;
ITU, intensive therapy unit; V/Q, ventilation–perfusion scan.
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demonstrate whether surgical outcomes for women
undergoing mastectomy and IBR have improved. If they
have not, this will focus the attention of breast and
plastic surgeons on relevant areas and highlight the
need for future research.
It is anticipated that the iBRA-2 study will strengthen
the collaborative network created by the iBRA (implant-
breast reconstruction evaluation) study through the suc-
cessful delivery of a second large-scale study in breast
and reconstructive surgery. The study will reinforce the
successful collaborative links between the breast and
plastic surgical communities and create additional
research capacity by broadening the network to include
oncologists. The engagement and involvement of a
wider community of trainees will lead to a new gener-
ation of consultants who understand the importance of
research and audit, who can and will participate in high-
quality collaborative studies resulting in more and better
research. We believe that this will ultimately improve out-
comes for patients.
The potential challenges to the success of this project
require consideration. The proposed data set is complex
and there is the risk of incomplete data. To address this,
we will extensively pilot the data collection tools prior to
study initiation. This will allow any redundant ﬁelds to
be removed and any ambiguities clariﬁed to optimise
data quality. Furthermore, the REDCap data manage-
ment system47 will be used for data collection. This
system has the functionality to include complex logic
such that only ﬁelds relevant to the procedure or indica-
tion initially entered are displayed in subsequent forms.
It is anticipated that this will minimise the burden of
data collection for local participants. Deﬁning a ‘delay’
to adjuvant treatment is also a potential challenge as dif-
ferent centres may record their ‘decision to treat’ at dif-
ferent points in the patient’s postoperative recovery,
especially if postoperative complications are experi-
enced. For this reason, we will collect ‘time to adjuvant
therapy’ in the study. This is deﬁned as the time (in
days) from the last cancer surgery to the ﬁrst dose of
chemotherapy or fraction of radiotherapy. It is antici-
pated that this will allow any potential local biases to be
addressed and comparable data to be obtained, so that
the true impact of IBR on time to adjuvant therapy can
be determined.
ETHICS AND DISSEMINATION
The proposed study will not affect clinical care and com-
pares outcomes to published clinical standards. Research
ethics approval is not required and this has been con-
ﬁrmed by the Health Research Authority (HRA) online
decision tool (http://www.hra-decisiontools.org.uk/
research/) and discussion with University of Bristol. A
study lead will be identiﬁed at each participating centre.
If the unit lead is a trainee, the named supervising consult-
ant will act as the principal investigator for the unit for
registration purposes. The study lead will be required to
register the audit and obtain local audit approvals for study
participation prior to starting patient recruitment. A copy of
the approval will be also forwarded to the iBRA-2 study
team. Patient consent is not required as no patient identiﬁ-
able data are being recorded and there is no risk to patients.
Following completion of the audit phase of the study,
proportionate ethical approval will be sought centrally
by the iBRA-2 study team to collect the locally main-
tained spreadsheets linking study ID number to patient
NHS numbers from participating centres. These data
will be stored securely on a University of Bristol server
until 5 years and 10 years, respectively, at which point a
search of the UK Cancer Registry database will be per-
formed. Only centres will appropriate ethical approvals
will be able to contribute their data to this phase of the
study.
The protocol will be disseminated via the collaborative
network, including Mammary Fold Breast Trainees’
Group, RSTN, ASiT and the National Research
Collaborative (NRC) as well as the professional associa-
tions the ABS and BAPRAS. The protocol and data col-
lection sheets will be available online (http://www.
ibrastudy.com). Individual centres will have access to
their own data and the length of time from mastectomy
to start of adjuvant therapy for each individual centre
will be calculated and compared with the national
average and quality standards determined by NICE. Data
will be fed back to centres at the end of the audit.
Overall audit results and results from individual centres
will be fed back to ABS and BAPRAS.
Collective data will be analysed and the results of the
study presented at appropriate scientiﬁc meetings and
published in peer-reviewed journals. The results can
then be used to inform patients and surgeons and aid
decision-making for women considering breast
reconstruction.
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